检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:孔珊 KONG Shan(Department of Hematology,the First Affiliated Hospital of China Medical University,Liaoning Province,Shenyang 110001,China)
机构地区:[1]中国医科大学附属第一医院血液科
出 处:《中国中医药现代远程教育》2019年第21期121-123,共3页Chinese Medicine Modern Distance Education of China
摘 要:目的观察四黄散外敷对血液肿瘤患者化疗所致静脉炎的防治效果。方法将63例化疗患者分为试验Ⅰ组、试验Ⅱ组和对照组,每组21例。对照组中出现静脉炎的患者给予50%硫酸镁湿敷治疗,试验Ⅰ组出现静脉炎的患者涂抹四黄散软膏,试验Ⅱ组化疗开始即涂抹四黄散软膏,观察各组患者的静脉炎发生率和处置情况。结果试验Ⅱ组的静脉炎发生率显著低于试验Ⅰ组和对照组(P<0.05),试验Ⅰ组和对照组的静脉炎发生率差异无统计学意义(P>0.05)。2个试验组的治疗有效率均显著高于对照组(P<0.05)。结论四黄散外敷对血液肿瘤患者化疗过程中的静脉炎具有较好的预防和治疗作用,可以降低静脉炎发生率,改善症状,可推广应用。Objective To observe the effect of Sihuangsan ointment in preventing phlebitis caused by chemotherapy. Methods 63 patients were randomly divided into control group(n=21), experimental group Ⅰ(n=21) and experimental group Ⅱ(n=21). Patients in the control group were treated with magnesium sulfate wet packing phlebitis ointment. Patients in the experimental group Ⅰ were treated with sihuangsan ointment when phlebitis occurs, while patients in the experimental group Ⅱ treated with Sihuangsan ointment when chemotherapy begins. The incidence rate and effective rate of phlebitis were compared between the 3 groups. Results The incidence rate of experimental group Ⅱ were significantly better than experimental group Ⅰ and control group( P <0.05), while the incidence rate of experimental group Ⅰ were not significantly better than control group, and there was no significant difference between the two groups(P>0.05). The effective rate of experimental group Ⅰ and experimental group Ⅱ were significantly better than control group(P<0.05). Conclusion Sihuangsan ointment in treating phlebitis caused by chemotherapy can obtain a good result and an obvious effective rate. Patients are willing to accept. It is worthy of clinical application.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.222